Current Topics and Perspectives in Surgical Management of Hepatocellular Carcinoma

Lünse, Sebastian; Heidecke, Claus–Dieter; Partecke, Lars Ivo

doi:10.15586/hepatocellularcarcinoma.2019.ch6

Cited by 4 publications

(3 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approximately 110,000 patients die of HCC every year in China, accounting for 45% of the death toll in the world ( 20 ). The therapeutic strategies for HCC mainly include chemotherapy, interventional therapy, surgery, liver transplantation and other comprehensive treatments ( 21 ). However, due to its high heterogeneity and high metastasis, it is still difficult to achieve good clinical effects ( 22 ).…”

Section: Discussionmentioning

confidence: 99%

Actin-binding protein anillin promotes the progression of hepatocellular carcinoma in vitro and in mice

et al. 2021

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a common type of tumor with high mortality worldwide. Investigations associated with the molecular etiology of HCC and screening novel therapeutic targets are still urgently in need. Anillin (ANLN), as a type of evolutionarily conserved actin-binding protein, is involved in multiple cellular processes. ANLN widely affected the progression and metastasis of several types of cancer, and its overexpression was frequently demonstrated in previous studies. The present study demonstrated high expression of ANLN in human HCC tissues, which was also associated the prognosis of patients with HCC. The associations between ANLN expression and the clinicopathological features were determined, including the number of tumor nodes (P=0.011) and tumor size (P=0.003) of patients with HCC. It was found that ANLN promoted cell proliferation, invasion and migration of HCC cells in vitro , and affected tumor growth in vivo . Therefore, ANLN is suggested as a promising therapeutic target for the treatment of HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Actin-binding protein anillin promotes the progression of hepatocellular carcinoma in vitro and in mice

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Most HCC patients are diagnosed in the advanced stages, in which several treatment modalities are followed, including the tyrosine kinase inhibitor targeted therapy (sorafenib), systematic chemotherapy using cytotoxic agents (cisplatin and 5-fluorouracil), trans-arterial chemoembolisation, external irradiation, liver resection and orthotopic liver transplantation (OLT). Despite the variety of treatment protocols, only OLT and surgical resection are curative [ 9 , 10 ]. Sorafenib, a multiple-target tyrosine kinase inhibitor, is utilized as the first-line therapy for patients with advanced HCC stage.…”

Section: Introductionmentioning

confidence: 99%

Multi-Omics Analysis Revealed a Significant Alteration of Critical Metabolic Pathways Due to Sorafenib-Resistance in Hep3B Cell Lines

Abushawish

Soliman

Giddey

et al. 2022

IJMS

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the second prominent cause of cancer-associated death worldwide. Usually, HCC is diagnosed in advanced stages, wherein sorafenib, a multiple target tyrosine kinase inhibitor, is used as the first line of treatment. Unfortunately, resistance to sorafenib is usually encountered within six months of treatment. Therefore, there is a critical need to identify the underlying reasons for drug resistance. In the present study, we investigated the proteomic and metabolomics alterations accompanying sorafenib resistance in hepatocellular carcinoma Hep3B cells by employing ultra-high-performance liquid chromatography quadrupole time of flight mass spectrometry (UHPLC-QTOF-MS). The Bruker Human Metabolome Database (HMDB) library was used to identify the differentially abundant metabolites through MetaboScape 4.0 software (Bruker). For protein annotation and identification, the Uniprot proteome for Homo sapiens (Human) database was utilized through MaxQuant. The results revealed that 27 metabolites and 18 proteins were significantly dysregulated due to sorafenib resistance in Hep3B cells compared to the parental phenotype. D-alanine, L-proline, o-tyrosine, succinic acid and phosphatidylcholine (PC, 16:0/16:0) were among the significantly altered metabolites. Ubiquitin carboxyl-terminal hydrolase isozyme L1, mitochondrial superoxide dismutase, UDP-glucose-6-dehydrogenase, sorbitol dehydrogenase and calpain small subunit 1 were among the significantly altered proteins. The findings revealed that resistant Hep3B cells demonstrated significant alterations in amino acid and nucleotide metabolic pathways, energy production pathways and other pathways related to cancer aggressiveness, such as migration, proliferation and drug-resistance. Joint pathway enrichment analysis unveiled unique pathways, including the antifolate resistance pathway and other important pathways that maintain cancer cells' survival, growth, and proliferation. Collectively, the results identified potential biomarkers for sorafenib-resistant HCC and gave insights into their role in chemotherapeutic drug resistance, cancer initiation, progression and aggressiveness, which may contribute to better prognosis and chemotherapeutic outcomes.

show abstract

“…All solitary tumors ≥2 cm were designated as stage A in the updated BCLC staging system (3). For stage A patients with preserved liver function and good performance status, surgical resection or liver transplantation is the recommended curative treatment (2)(3)(4)(5).…”

Section: Introductionmentioning

confidence: 99%

Prognostic Stratification Based on a Novel Nomogram for Solitary Large Hepatocellular Carcinoma After Curative Resection

Zhuang

Zhou

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Solitary large hepatocellular carcinoma (SLHCC) is a specific subtype of HCC with unique characteristics. It is of great interest to assess and stratify the prognosis of SLHCCs after curative resection. In this study, we tried to construct a prognostic nomogram for SLHCC following curative resection through a retrospective analysis of 202 SLHCC cases. Seven prognostic factors were identified and integrated to establish a novel prognostic nomogram, which included tumor size, microvascular invasion, tumor differentiation, Ki67 (%), α-fetoprotein (AFP), carbohydrate antigen 125 (CA125), and HBsAg status. The Harrell's concordance index (C-index) of the nomogram for overall survival (OS) in the training, validation, and whole sets was 0.752, 0.703, and 0.733, respectively. Furthermore, the area under the curve (AUC) of the receiver operating characteristic (ROC) curve of the nomogram for predicting 1-, 3-, and 5-year OS indicated that the nomogram had an optimal discrimination of the prognostic prediction for SLHCC. The total score of each patient was calculated based on the nomogram, and patients were divided into three subgroups: low-risk group (total score ≦ 107), medium-risk group (107 < total score ≤ 125), and high-risk group (total score > 125). The 1-, 3-, and 5-year OS rates of the low-risk, medium-risk, and high-risk groups in the whole set were 89.3 vs. 70.1 vs. 33.3%, 76.6 vs. 37.8 vs. 14.5%, and 69.8 vs. 25.1 vs. 12.5%, respectively ( P < 0.001). Similar results were shown in terms of the recurrence-free survival (RFS) rate. By analyzing 101 cases of recurrent tumors, transarterial chemoembolization (TACE) plus radiofrequency ablation (RFA)/surgery was found to prolong patient survival when compared to TACE alone in the low-risk group, but not in the medium/high-risk group. In conclusion, our prognostic nomogram successfully stratifies the prognosis for SLHCC after curative resection, which deserves further study in future clinical practice.

show abstract

Current Topics and Perspectives in Surgical Management of Hepatocellular Carcinoma

Cited by 4 publications

References 91 publications

Actin-binding protein anillin promotes the progression of hepatocellular carcinoma in vitro and in mice

Actin-binding protein anillin promotes the progression of hepatocellular carcinoma in vitro and in mice

Multi-Omics Analysis Revealed a Significant Alteration of Critical Metabolic Pathways Due to Sorafenib-Resistance in Hep3B Cell Lines

Prognostic Stratification Based on a Novel Nomogram for Solitary Large Hepatocellular Carcinoma After Curative Resection

Contact Info

Product

Resources

About